Posted by Michael Wonder on 05 Aug 2023
GSK's Arexvy, the first respiratory syncytial virus vaccine for older adults approved in Canada
4 August 2023 - Approval of Arexvy was based on a comprehensive Phase III clinical trial program that showed high vaccine efficacy of 82.6% for prevention of lower respiratory tract disease caused by RSV in older adults, and 94.6% efficacy in those with underlying medical conditions.
Arexvy (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.
